A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Qi-Zhi-Wei-Tong Granules on Postprandial Distress Syndrome-Predominant Functional Dyspepsia

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2018 Jun 27

PMID 29941708

Citations 6

Authors

Qing Su

Sheng-Liang Chen

Hua-Hong Wang

Lie-Xin Liang

Ning Dai

Bin Lyu

Jun Zhang

Rong-Quan Wang

Ya-Li Zhang

Yue Yu

Jin-Song Liu

Xiao-Hua Hou

Affiliations

Soon will be listed here.

Abstract

Background: Functional dyspepsia (FD) is a common upper gastrointestinal disorder worldwide, but the current treatments for FD are still unsatisfactory. The aims of this study were to investigate the efficacy and safety of Qi-Zhi-Wei-Tong granules in patients with postprandial distress syndrome (PDS)-predominant FD.

Methods: The study was conducted as a randomized, double-blinded, multicenter, placebo-controlled design in 197 patients with PDS. All participants received placebo treatment for 1 week. Patients whose total symptom score decreased by <50% after the placebo treatment were recruited into the 4-week treatment period, in which they were randomly assigned to be treated with either Qi-Zhi-Wei-Tong granules or placebo. The patients were then followed for 2 weeks without any treatment. Dyspeptic symptoms were scored at weeks 2 and 4 during the random treatment period and 2 weeks after the treatment. Anxiety and depression symptoms were also scored and compared.

Results: (1) The total effective rates in the Qi-Zhi-Wei-Tong granules group at weeks 2 and 4 during the random treatment period and 2 weeks after treatment were all significantly higher than those in the placebo group (38.82% vs. 8.75%, P < 0.001; 69.14% vs. 16.25%, P < 0.001; 77.65% vs. 21.25%, P < 0.001). (2) The total dyspeptic symptoms scores in the Qi-Zhi-Wei-Tong granules group at weeks 2 and 4 and 2 weeks after treatment were significantly lower than those in the placebo group. (3) The severity and frequency of each dyspeptic symptom at weeks 2 and 4 and the follow-up period were all significantly lower than those in the placebo group. (4) The anxiety scores in the Qi-Zhi-Wei-Tong granules group were significantly lower than those in the placebo group. (5) Qi-Zhi-Wei-Tong granules did not have more adverse effects than the placebo.

Conclusion: Qi-Zhi-Wei-Tong granules offer significant symptomatic improvement in PDS with no more adverse effects than placebo.

Trial Registration: https://clinicaltrials.gov/, NCT02460601.

Citing Articles

Traditional Chinese medicine for functional gastrointestinal disorders and inflammatory bowel disease: narrative review of the evidence and potential mechanisms involving the brain-gut axis.

Liu R, Luo Y, Ma J, Zhang Q, Sheng Y, Li J Front Pharmacol. 2024; 15:1444922.

PMID: 39355776 PMC: 11443704. DOI: 10.3389/fphar.2024.1444922.

Global trends in research related to functional dyspepsia and anxiety or depression over the past two decades: a bibliometric analysis.

Huang Q, Yuan H, Li Q, Li Y, Geng S, Zhu Y Front Neurosci. 2023; 17:1218001.

PMID: 38027507 PMC: 10651763. DOI: 10.3389/fnins.2023.1218001.

Clinical efficacy of decoction in the treatment of functional dyspepsia and its influence on life quality.

Han J, Yang Q, Xu X Am J Transl Res. 2021; 13(10):11662-11670.

PMID: 34786092 PMC: 8581920.

Clinical study on post evaluation after listing of Qizhi Weitong granules: Study protocol clinical trial (SPIRIT compliant).

Xu L, Zhang J, Li J, Lv L, Zhang Z, Wang F Medicine (Baltimore). 2020; 99(16):e19758.

PMID: 32311977 PMC: 7220035. DOI: 10.1097/MD.0000000000019758.

Efficacy of Weikang Pian in Patients with Functional Dyspepsia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial.

Yan L, Yu L, Zhao L, Wang D, Qin D, Fan H Evid Based Complement Alternat Med. 2019; 2019:4827046.

PMID: 31781270 PMC: 6874944. DOI: 10.1155/2019/4827046.

References

Tack J, Talley N, Camilleri M, Holtmann G, Hu P, Malagelada J . Functional gastroduodenal disorders. Gastroenterology. 2006; 130(5):1466-79. DOI: 10.1053/j.gastro.2005.11.059. View

Van Oudenhove L, Aziz Q . The role of psychosocial factors and psychiatric disorders in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013; 10(3):158-67. DOI: 10.1038/nrgastro.2013.10. View

Fang Y, Shan D, Liu J, Xu W, Li C, Wu H . Effect of constituents from Fructus Aurantii Immaturus and Radix Paeoniae Alba on gastrointestinal movement. Planta Med. 2008; 75(1):24-31. DOI: 10.1055/s-0028-1088342. View

Holtmann G, Talley N, Liebregts T, Adam B, Parow C . A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006; 354(8):832-40. DOI: 10.1056/NEJMoa052639. View

Meier R, Hengstler P, Weber F, Maurer H, Bommeli C, Brignoli R . The Tibetan herbal formula Padma Digestin in functional dyspepsia: an open-label study. Forsch Komplementmed. 2013; 20 Suppl 2:2-7. DOI: 10.1159/000351086. View

Quigley E . Cisapride: what can we learn from the rise and fall of a prokinetic?. J Dig Dis. 2011; 12(3):147-56. DOI: 10.1111/j.1751-2980.2011.00491.x. View

Arai M, Matsumura T, Tsuchiya N, Sadakane C, Inami R, Suzuki T . Rikkunshito improves the symptoms in patients with functional dyspepsia, accompanied by an increase in the level of plasma ghrelin. Hepatogastroenterology. 2012; 59(113):62-6. DOI: 10.5754/hge11246. View

Spiller R . Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med. 1999; 107(5A):91S-97S. DOI: 10.1016/s0002-9343(99)00086-8. View

Mearin F, de Ribot X, Balboa A, Salas A, Varas M, Cucala M . Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia?. Gut. 1995; 37(1):47-51. PMC: 1382767. DOI: 10.1136/gut.37.1.47. View

10.

Canan O, Ozcay F, Ozbay-Hosnut F, Yazici C, Bilezikci B . Value of the Likert dyspepsia scale in differentiation of functional and organic dyspepsia in children. J Pediatr Gastroenterol Nutr. 2011; 52(4):392-8. DOI: 10.1097/MPG.0b013e3181fea0a9. View

11.

Drossman D . The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006; 130(5):1377-90. DOI: 10.1053/j.gastro.2006.03.008. View

12.

Zhang C, Guo L . Dalitong granule combined with electroacupuncture in the treatment of functional dyspepsia: A randomized controlled trial. Chin J Integr Med. 2015; 21(10):743-50. DOI: 10.1007/s11655-015-2175-5. View

13.

Lv L, Wang F, Ma X, Li Z, Huang S, Shi Z . Efficacy and safety of Xiangsha Liujunzi granules for functional dyspepsia: A multi-center randomized double-blind placebo-controlled clinical study. World J Gastroenterol. 2017; 23(30):5589-5601. PMC: 5558122. DOI: 10.3748/wjg.v23.i30.5589. View

14.

Lacy B, Talley N, Locke 3rd G, Bouras E, DiBaise J, El-Serag H . Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther. 2012; 36(1):3-15. PMC: 3970847. DOI: 10.1111/j.1365-2036.2012.05128.x. View

15.

Jeong J, Choi M, Cho Y, Lee S, Oh J, Park J . Chronic gastrointestinal symptoms and quality of life in the Korean population. World J Gastroenterol. 2008; 14(41):6388-94. PMC: 2766123. DOI: 10.3748/wjg.14.6388. View

16.

Suzuki H, Kusunoki H, Kamiya T, Futagami S, Yamaguchi Y, Nishizawa T . Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United European Gastroenterol J. 2014; 1(6):445-52. PMC: 4040742. DOI: 10.1177/2050640613510904. View

17.

Holtmann G, Kutscher S, Haag S, Langkafel M, Heuft G, Neufang-Hueber J . Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia; a randomized, double-blind placebo-controlled crossover study. Dig Dis Sci. 2004; 49(4):672-9. DOI: 10.1023/b:ddas.0000026317.00071.75. View

18.

Camilleri M, Stanghellini V . Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013; 10(3):187-94. DOI: 10.1038/nrgastro.2013.11. View

19.

Lan L, Yu J, Chen Y, Zhong Y, Zhang H, Jia C . Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia. World J Gastroenterol. 2011; 17(27):3242-7. PMC: 3158401. DOI: 10.3748/wjg.v17.i27.3242. View

20.

Chang C, Lin M . DL-Tetrahydropalmatine may act through inhibition of amygdaloid release of dopamine to inhibit an epileptic attack in rats. Neurosci Lett. 2001; 307(3):163-6. DOI: 10.1016/s0304-3940(01)01962-0. View